AGEN - LONGAGEN, a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Leerink Global Biopharma Conference on March 11th - 13th in Miami Beac
−13.88USD
−245.76 MUSD
156.31 MUSD
About Agenus Inc.
Sector
Industry
CEO
Garo H. Armen
Website
Headquarters
Lexington
Employees (FY)
389
Founded
1994
ISIN
US00847G8042
FIGI
BBG000C8SWQ9
Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.
AGEN | Agenus Inc. Healthcare | Biotechnology | USA | NASDAQ
📈 Technical Chart Patterns & Trend Analysis 📉
Identifying potential trading opportunities based on trend analysis:
After forming Bullish divergence the price charts signals a potential trend reversal, indicating a shift from a downtrend to a possible uptrend.
AGENUS Stock Chart Fibonacci Analysis 071023 Trading Idea
1) Find a FIBO slingshot
2) Check FIBO 61.80% level
3) Entry Point > 1.7/61.80%
Chart time frame : B
A) 15 min(1W-3M)
B) 1 hr(3M-6M)
C) 4 hr(6M-1year)
D) 1 day(1-3years)
Stock progress : A
A) Keep rising over 61.80% resistance
B) 61.80% resistance
C) Hit the bottom
D) Hit the top
AGENUS going back inAgenus NASDAQ:AGEN is a stock that I have not followed since they were forced (unfairly) by the FDA to pull their NDA for balstilimab. However recently price action has started to look favourable and this is in conjuction with ASCO where the company is presenting clinical data from 2 trials.
Gap Fill + Great earnings reportThe earnings report is expected to be good and therefore i think there will at least be a gap fill up to 5.
Looking at the macd it also looks like we are gonna have a green crossover to the upwards movement. I wouldsay bullish.
I could be completely wrong and this should be taken with a grain of s
AGEN Daily TimeframeSNIPER STRATEGY (new version)
It works ALMOST ON ANY CHART.
It produces Weak, Medium and Strong signals based on consisting elements.
NOT ALL TARGETS CAN BE ACHIEVED, let's make that clear.
TARGETS OR ENTRY PRICES ARE STRONG SUPPORT AND RESISTANCE LEVELS.
ENTRY PRICE BLACK COLOR
TARGETS
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of AGEN is 6.54 USD — it has increased by 0.54% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Agenus Inc. stocks are traded under the ticker AGEN.
Agenus Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Agenus Inc. has a max estimate of 160.00 USD and a min estimate of 60.00 USD.
AGEN earnings for the last quarter are −3.20 USD whereas the estimation was −3.90 USD which accounts for 17.98% surprise. Estimated earnings for the next quarter are −1.07 USD. See more details about Agenus Inc. earnings.
Agenus Inc. revenue for the last quarter amounts to 24.31 M USD despite the estimated figure of 24.33 M USD. In the next quarter revenue is expected to reach 47.05 M USD.
Yes, you can track Agenus Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, AGEN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Agenus Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 389.00 employees. See our rating of the largest employees — is Agenus Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Agenus Inc. EBITDA is −146.52 M USD, and current EBITDA margin is −93.73%. See more stats in Agenus Inc. financial statements.